Rechallenge of ponatinib in chronic myeloid leukaemia after hepatotoxicity

Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm associated with an oncogenic fusion gene breakpoint cluster region-Abelson (BCR-ABL) encoding a protein with tyrosine kinase activity. Trend of liver function test prior tocommencement of treatment with ponatinib The incidence of serum...

Full description

Saved in:
Bibliographic Details
Published in:Hong Kong medical journal = Xianggang yi xue za zhi 2019-04, Vol.25 (2), p.162
Main Authors: Boo, Y L, Liam, Christopher CK, Toh, S G, Lim, S M
Format: Article
Language:chi ; eng
Subjects:
Biopsy
Hematology
Leukemia
Liver
Mutation
Patients
Steroids
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukaemia (CML) is a myeloproliferative neoplasm associated with an oncogenic fusion gene breakpoint cluster region-Abelson (BCR-ABL) encoding a protein with tyrosine kinase activity. Trend of liver function test prior tocommencement of treatment with ponatinib The incidence of serum alanine aminotransferase and aspartate aminotransferase elevations has been reported as 56% for all grades, and 8% for Grades 3 or 4.1 These adverse events were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.4 The presence of serum aminotransferase levels above 3 times the normal upper limit should lead to dose reduction or temporary cessation of treatment, with resumption at a lower dose once levels normalise. In patients with clinically apparent liver injury and jaundice, treatment should be discontinued.1 In a phase I trial of ponatinib, observed adverse events, which included hepatotoxicity, were dose-dependent and reported as self-limiting in most of the
ISSN:1024-2708
2226-8707
DOI:10.12809/hkmj187420